Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
Recruiting in Palo Alto (17 mi)
+1 other location
Age: Any Age
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Salarius Pharmaceuticals, LLC
No Placebo Group
Trial Summary
What is the purpose of this trial?Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.
Eligibility Criteria
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Sp-2577Experimental Treatment1 Intervention
Twice-daily administration of oral SP-2577
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
HonorHealthScottsdale, AZ
Sarcoma Oncology Research CenterSanta Monica, CA
Loading ...
Who is running the clinical trial?
Salarius Pharmaceuticals, LLCLead Sponsor